Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01878123 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis

A Phase 1 study of Rheumatoid Arthritis, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
3
Study locations

NCT01878123 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by MedImmune. The registered enrollment target is 26 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01878123, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
3
Study locations

Study Summary

This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time in human study of AMP-110 in adult subjects with rheumatoid arthritis.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • OTHER Placebo
  • BIOLOGICAL AMP-110

Study Locations (3)

Alabama

  • Pinnacle Research Group, LLC - Anniston

Pennsylvania

  • Altoona Center for Clinical Research - Duncansville

Texas

  • Metroplex Clinical Research Center - Dallas

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2013-04
Est. Completion 2014-07
Phase Phase 1

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01878123

The ClinicalTrials.gov registry entry for NCT01878123 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01878123 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Alabama, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT01878123 about?

NCT01878123 is a clinical study titled "Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis". This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time in human study of AMP-110 in adult subjects with rheumatoid arthritis.

What is the current status of trial NCT01878123?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-04. Estimated completion is 2014-07.

What conditions does trial NCT01878123 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01878123?

The interventions under investigation include: Placebo (OTHER), AMP-110 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01878123?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01878123 being conducted?

This trial has 3 study locations across Alabama, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.